{"id":"trafermin-0-01-spray","safety":{"commonSideEffects":[{"rate":"null","effect":"Application site reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Trafermin works by stimulating angiogenesis and promoting the proliferation and migration of various cell types involved in wound healing. This leads to improved tissue repair and regeneration.","oneSentence":"Trafermin is a recombinant human fibroblast growth factor 2 (FGF-2) used to promote wound healing.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:42.231Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of diabetic foot ulcers"}]},"trialDetails":[{"nctId":"NCT01217476","phase":"PHASE3","title":"The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study","status":"COMPLETED","sponsor":"Olympus Biotech Corporation","startDate":"2010-12","conditions":"Diabetic Foot Ulcer of Neuropathic Origin","enrollment":207},{"nctId":"NCT01217463","phase":"PHASE3","title":"The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study","status":"COMPLETED","sponsor":"Olympus Biotech Corporation","startDate":"2010-11","conditions":"Diabetic Foot Ulcer of Neuropathic Origin","enrollment":201}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Trafermin 0.01% spray","genericName":"Trafermin 0.01% spray","companyName":"Olympus Biotech Corporation","companyId":"olympus-biotech-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trafermin 0.01% spray is a fibroblast growth factor receptor 2 agonist, classified as a protein drug. It has been studied in a Phase III clinical trial for the treatment of diabetic foot ulcers of neuropathic origin.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}